Idenix Pharmaceuticals (IDIX)

[mskatiescarletohara]

that VRTX could obtain accelerated approval for VX-950 based on only the phase-2 program.

I've always felt they would use the 24 week data from the pivotals, along with data from the Phase II program. Especially now, that McHutchison has projected treatment can be shortened in some patients. Looks like early 2009 will be potential marketing approval.

katie...